A phase 1/2 trial of SLN124 in myeloproliferative neoplasms, run by Silence Therapeutics plc, active and no longer recruiting.
Study to Assess SLN124 in Patients With Polycythemia Vera is a phase 1/2 interventional study registered as NCT05499013 by Silence Therapeutics plc, with 69 participants enrolled, started 2023-01-26 and due to reach its primary completion in 2026-09. Interventions recorded: SLN124 and Placebo.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.